DE68922614D1 - Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen. - Google Patents

Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen.

Info

Publication number
DE68922614D1
DE68922614D1 DE68922614T DE68922614T DE68922614D1 DE 68922614 D1 DE68922614 D1 DE 68922614D1 DE 68922614 T DE68922614 T DE 68922614T DE 68922614 T DE68922614 T DE 68922614T DE 68922614 D1 DE68922614 D1 DE 68922614D1
Authority
DE
Germany
Prior art keywords
oncogenes
oligonucleotides
antisense
myb
myb proto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68922614T
Other languages
English (en)
Other versions
DE68922614T2 (de
Inventor
Alan Gewirtz
Bruno Calabretta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of DE68922614D1 publication Critical patent/DE68922614D1/de
Application granted granted Critical
Publication of DE68922614T2 publication Critical patent/DE68922614T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
DE68922614T 1988-11-07 1989-11-03 Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen. Expired - Fee Related DE68922614T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26790188A 1988-11-07 1988-11-07
US40802689A 1989-09-09 1989-09-09
US07/427,659 US5098890A (en) 1988-11-07 1989-10-27 Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
PCT/US1989/004927 WO1990005445A1 (en) 1988-11-07 1989-11-03 Antisense oligonucleotides to c-myb proto-oncogene and uses thereof

Publications (2)

Publication Number Publication Date
DE68922614D1 true DE68922614D1 (de) 1995-06-14
DE68922614T2 DE68922614T2 (de) 1996-01-11

Family

ID=27402019

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68922614T Expired - Fee Related DE68922614T2 (de) 1988-11-07 1989-11-03 Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen.

Country Status (7)

Country Link
US (1) US5098890A (de)
EP (1) EP0424476B1 (de)
AT (1) ATE122234T1 (de)
AU (1) AU641636B2 (de)
DE (1) DE68922614T2 (de)
DK (1) DK3591D0 (de)
WO (1) WO1990005445A1 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6841541B1 (en) 1992-02-21 2005-01-11 The Trustees Of The University Of Pennsylvania Regulation of BCL-2-gene expression
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
IE911115A1 (en) * 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5242906A (en) * 1991-04-22 1993-09-07 University Of North Carolina At Chapel Hill Antisense oligonucleotides against Epstein-Barr virus
EP0585399A4 (en) * 1991-05-23 1995-11-15 Univ Temple Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
EP0558697A1 (de) * 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Lokale oligonukleotiden Behandlung
AU659482B2 (en) * 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU2449092A (en) * 1991-08-09 1993-03-02 New England Deaconess Hospital A method of inducing hemoglobin synthesis in red blood cells and uses therefor
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
WO1993009437A2 (en) * 1991-10-31 1993-05-13 Matritech, Inc. Nuclear matrix protein fluid assay
JPH07501525A (ja) * 1991-11-15 1995-02-16 テンプル　ユニバーシティ　‐　オブ　ザ　コモンウェルス　システム　オブ　ハイヤー　エデュケーション ｃ−ｍｙｂプロトオンコジーンに対するアンチセンスオリゴヌクレオチドによる黒色腫の処置
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
EP0644889A4 (de) * 1991-12-24 1996-01-10 Isis Pharmaceuticals Inc ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULATION VON-g(b)-AMYLOID.
WO1993017125A1 (en) * 1992-02-19 1993-09-02 Baylor College Of Medicine Oligonucleotide modulation of cell growth
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
AU675638B2 (en) * 1992-03-16 1997-02-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US5948898A (en) * 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US5936079A (en) 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
EP0647270B1 (de) * 1992-06-22 2004-01-07 Matritech, Inc. Neuartige marker maligner zelltypen in der inneren nukleären matrix
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
AU5136693A (en) * 1992-10-01 1994-04-26 Thomas Jefferson University Antisense oligonucleotides to b myb proto-oncogene
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5395825A (en) * 1993-03-10 1995-03-07 Yale University Fertility regulation with transforming growth factor β
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
DE69426804T4 (de) * 1993-05-27 2005-10-13 Icos Corp., Bothell Cyclisch gmp bindende cyclisch gmp spezifische phosphodiesterase materialien und verfahren.
US5473060A (en) * 1993-07-02 1995-12-05 Lynx Therapeutics, Inc. Oligonucleotide clamps having diagnostic applications
US5571903A (en) * 1993-07-09 1996-11-05 Lynx Therapeutics, Inc. Auto-ligating oligonucleotide compounds
EP0708829B8 (de) * 1993-07-10 2004-07-21 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Antisense-nukleinsäure enthaltende pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zelltod, und zur behandlung von neoplasmen
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
ATE247128T1 (de) 1993-09-03 2003-08-15 Isis Pharmaceuticals Inc Aminoderivatisierte nukleoside und oligonukleoside
PT1584682E (pt) * 1993-09-20 2009-08-03 Univ Pennsylvania Regulação da expressão do gene bcl-2
US5807838A (en) * 1994-09-23 1998-09-15 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5814619A (en) * 1994-04-08 1998-09-29 Isis Pharmacuticals, Inc. Oligonucleotide inhibition of P120
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
KR100211178B1 (ko) * 1994-05-31 1999-07-15 파샬 비. 린네 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5994320A (en) * 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
US5830658A (en) * 1995-05-31 1998-11-03 Lynx Therapeutics, Inc. Convergent synthesis of branched and multiply connected macromolecular structures
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
EP0938320B2 (de) * 1996-03-26 2014-06-18 Michael S. Kopreski Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
WO1998042722A1 (en) 1997-03-21 1998-10-01 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
EP1045918B1 (de) 1998-01-12 2008-08-20 Pedro Jose G protein-verwandte kinasemutanten in der essentiellen hypertonie
EP1080103A4 (de) * 1998-05-21 2003-07-02 Isis Pharmaceuticals Inc Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US20030181412A1 (en) * 1999-12-21 2003-09-25 Ingeneus Corporation Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses
AU2001263810A1 (en) * 2000-03-27 2001-10-08 Bayer Aktiengesellschaft Regulation of human c-myb-related genes
EP1158055A1 (de) 2000-05-26 2001-11-28 Xu Qi University of Teaxs Laboratoire de Leucémie Chen Verfahren zur Diagnose von Krebs
ES2349137T3 (es) * 2000-06-20 2010-12-28 Dainippon Sumitomo Pharma Co., Ltd. Preparación para transferir oligonucleótidos.
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20040147473A1 (en) * 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
KR100426453B1 (ko) 2000-11-28 2004-04-13 김진우 인간 자궁경부암 2 원암 유전자 및 이에 의해 코딩되는단백질, 이를 포함하는 발현벡터 및 이 벡터로 형질전환된세포
EP1392366A4 (de) * 2001-04-13 2005-01-19 Population Council Inc Kernrezeptor-vermittelte einführung eines pna proteins in zellkerne
CN1313158C (zh) * 2001-06-20 2007-05-02 大日本住友制药株式会社 促进核酸转移的方法
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
AU2002327308A1 (en) * 2001-07-25 2003-02-17 Oncomedx Inc. Methods for evaluating pathologic conditions using extracellular rna
US20030049203A1 (en) * 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
CA2474414C (en) * 2002-02-01 2018-03-06 Mcgill University Oligonucleotides comprising alternating segments and uses thereof
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
WO2004071453A2 (en) 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
US7635560B2 (en) * 2003-04-17 2009-12-22 Genesis Group Inc. Pygopus in diagnosis and treatment of cancer
CA2524883C (en) * 2003-05-16 2014-07-22 Universite Laval Potassium-chloride cotransporter kcc2 modulation for treatment of pain
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
US20040248101A1 (en) * 2003-06-03 2004-12-09 Cytogenix, Inc. Identification of novel antibacteria agents by screening the single-stranded DNA expression library
JP4954550B2 (ja) * 2003-12-19 2012-06-20 大日本住友製薬株式会社 新規な核酸導入法
JP2007537167A (ja) * 2004-05-14 2007-12-20 ユニヴェルシテ ラヴァル ホスホリパーゼｃガンマの調節、並びにそれによる疼痛及び侵害受容の制御
US7700272B2 (en) * 2004-06-09 2010-04-20 Mcgill University Polynucleotides encoding acetylcholine-gated chloride channel subunits of Caenorhabditis elegans
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
EP2057284A4 (de) * 2006-08-04 2011-06-29 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur modulation von jnk-proteinen
WO2008092099A2 (en) * 2007-01-26 2008-07-31 Rosetta Genomics, Ltd. Compositions and methods for treating hematopoietic malignancies
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
WO2009046483A1 (en) * 2007-10-08 2009-04-16 The Walter And Eliza Hall Institute Of Medical Research Therapeutic protocol for the treatment or prevention of thrombocytopenia
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
HUE054204T2 (hu) 2014-09-05 2021-08-30 Rsem Lp Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action

Also Published As

Publication number Publication date
DK3591D0 (da) 1991-01-09
AU641636B2 (en) 1993-09-30
US5098890A (en) 1992-03-24
DE68922614T2 (de) 1996-01-11
AU5035090A (en) 1990-06-12
EP0424476A1 (de) 1991-05-02
ATE122234T1 (de) 1995-05-15
EP0424476A4 (en) 1992-05-06
EP0424476B1 (de) 1995-05-10
WO1990005445A1 (en) 1990-05-31

Similar Documents

Publication Publication Date Title
DE68922614D1 (de) Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen.
US5446137B1 (en) Oligonucleotides containing 4'-substituted nucleotides
NZ289028A (en) Use of antisense nucleic acids in the treatment of skin disease
IT9083334A0 (it) Procedimento per l'estrazione e la purificazione di dna genomico umano
EP1905304A3 (de) Behandlung von Neoplasmen mit Viren
EP0219830A3 (en) Hair treating composition containing cationic organic polymer and carboxyfunctional silicone
HK164395A (en) Use of 3'-azido-3'-deoxythymidine in the treatment or prophylaxis of human retroviral infections
EE03512B1 (et) Epinastiin kasutamiseks valude ravis
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
PL327061A1 (en) Treatment of hiv infection effects occured in the central nervous system by means o vx-478 preparation used solely or in combination wit azt or 3tc
DE69715482D1 (de) Herstellung von 1,1,1,3,3-Pentachlorbutan und von 1,1,1,3,3-Pentafluorbutan
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
HUP9802130A3 (en) Heat treatment of carbon materials
EE9600018A (et) 2,9-diasendatud puriin-6-oonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
HUP9903249A3 (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
FI940139A0 (fi) Alkenyyliryhmiä sisältäviä siloksaanikopolymeerejä, niiden valmistus ja käyttö
DE69116810D1 (de) Fluoralkylgruppe enthaltende Organosiliciumoligomer, Verfahren zu deren Herstellung und Oberflächenbehandlungsmittel
FR2712492B1 (fr) Compositions cosmétiques à base d'eaux thermales et leur procédé de préparation.
IT1241123B (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
NL193614B (nl) Werkwijze voor de bereiding van 4,5-tri- en -tetramethyleen-4-isothiazoline-3-onen, 2-alkyl- of -aralkylthio-1-cycloalkeencarbonamiden ten gebruike bij deze werkwijze en werkwijze voor de bereiding van de 2-alkyl- of -aralkylthio-1-cycloalkeencarbonamiden.
PL337665A1 (en) (s) 2-methylamine-2-phenyl-n-butyl-3,4,5-trimethoxybezoate and application thereof in treating long-lasting pains
CA2004364A1 (en) Antisense oligonucleotides to c-myb oncogene and uses thereof
Salmon Endoscopic treatment of gastro-intestinal tumours: can surgery be avoided?
EP0410393A3 (en) Polysiloxane copolymer useful for hair treating
FR2722501B1 (fr) Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee